Finally, a Vaccine for Cancer
Finally, a Vaccine for Cancer
Podcast22 min 38 sec
Listen to Episode
Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights
  • MRK and MRNA offer a promising but high-risk oncology opportunity through their personalized melanoma vaccine, which was associated with a 42% lower recurrence likelihood over two years when combined with an immunotherapy.
  • Treat the results as an early signal, not a buy catalyst: the vaccine remains experimental, and long-term outcomes, costs, and commercial potential are uncertain.
  • Monitor the companies’ planned FDA application and longer-term trial results before making an investment decision.
Detailed Analysis

Merck & Co. (MRK)

  • Merck is one of the companies behind an experimental personalized mRNA vaccine for melanoma, developed in partnership with Moderna.
  • The vaccine was tested in people whose melanoma had been surgically removed but remained at high risk of returning. In combination with an immune checkpoint inhibitor, it was associated with a 42% lower likelihood of recurrence over the reported follow-up period.
  • The companies plan to apply for FDA approval. The transcript does not give an application date or a price target.

Takeaways

  • The results point to a potential oncology opportunity for Merck, but the vaccine is still experimental and the reported data cover only two years. Long-term survival results and regulatory outcomes remain unknown.
  • Watch for further trial results and FDA developments; the discussion does not establish that the treatment will work for other cancers or how much revenue it could generate.

Moderna (MRNA)

  • Moderna is partnering with Merck on the personalized mRNA melanoma vaccine. The approach uses tumor sequencing to select mutations and create an individualized vaccine intended to help the immune system recognize cancer cells.
  • The transcript says Moderna’s experience manufacturing mRNA vaccines quickly and at scale, developed during the COVID-19 period, helped make this kind of customized vaccine feasible.
  • The companies plan to apply for FDA approval. The vaccine was studied alongside an immune checkpoint inhibitor, rather than as a standalone treatment.

Takeaways

  • The melanoma results support the potential of mRNA technology in cancer treatment, but they do not establish how broadly the approach can be used or whether it will be commercially viable.
  • A key challenge is cost: making a vaccine for an individual patient is expected to be expensive. Longer-term data and evidence in other cancers will be important to assess the opportunity.

Personalized Cancer Vaccines and Immunotherapy

  • The discussion describes a treatment approach that combines a patient-specific vaccine with an immune checkpoint inhibitor, which removes some of the immune system’s “brakes.”
  • Researchers are studying whether similar vaccines could help treat other cancers. A small pancreatic cancer study involving 16 patients showed encouraging early results after surgery, and a larger randomized study is ongoing.
  • Researchers are also investigating “off-the-shelf” vaccines for prevention in people at elevated risk, such as those with BRCA1 or BRCA2 mutations or certain precursor conditions. The transcript says this work is still years away and could fail.

Takeaways

  • The melanoma findings make personalized cancer vaccines a notable biotechnology research theme, but they are not proof of a broadly effective cancer treatment.
  • Relevant milestones to follow include longer-term melanoma results, results from the larger pancreatic cancer study, FDA decisions, and evidence that the approach can work across additional cancers.
  • The transcript specifically flags limited long-term data, uncertainty about effectiveness beyond melanoma, and high potential production costs as risks.
Ask about this postAnswers are grounded in this post's content.
Episode Description
An experimental vaccine has been found to prevent recurrence of melanoma. Scientists hope it won’t be the last.  A new, experimental vaccine could become the first of its kind to treat cancer. Nina Agrawal, a health reporter for The New York Times, explains how a century-old idea is finally becoming a reality and where this breakthrough could lead next. Guest: Nina Agrawal, a health reporter for The New York Times. Background reading:  The first-of-its-kind vaccine has ushered in new hope for cancer patients. Drug makers reported that the cancer vaccine cut the risk of melanoma recurrence. Photo: Brendan Mcdermid/Reuters For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. Subscribe today at nytimes.com/podcasts or on Apple Podcasts, Spotify and Amazon Music. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
About The Daily
The Daily

The Daily

By The New York Times

This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro, Rachel Abrams and Natalie Kitroeff. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Listen to this podcast in New York Times Audio, our new iOS app for news subscribers. Download now at nytimes.com/audioapp